Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
FreeHealth Equity ACS is using an AI-powered platform in the largest-ever population study of Black womenTime and resources freed up from data management will go to outreach and access August 02, 2024Vol.50 No.31By Jacquelyn Cobb
FreeIn the Archives Suzanne Conzen discusses research, leadership, and mentorship on the UChicago Cancer Luminaries Podcast August 02, 2024Vol.50 No.31
Regulatory News ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications July 26, 2024Vol.50 No.30By Jacquelyn Cobb and Paul Goldberg
News AnalysisWhite House Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025 July 26, 2024Vol.50 No.30By McKenzie Prillaman
Letter To The Editor Tweaking the existing systems is not the answer to drug shortages July 26, 2024Vol.50 No.30
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
FreeIn the Archives Before the Olympics were smoke-free, tobacco brand deals ran rampant July 26, 2024Vol.50 No.30
Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” July 19, 2024Vol.50 No.29By Jacquelyn Cobb
Free A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital July 19, 2024Vol.50 No.29By Paul Goldberg
